FR3110165B1 - Nouveaux composés fluorescents pour le marquage de tissu tumoral - Google Patents

Nouveaux composés fluorescents pour le marquage de tissu tumoral Download PDF

Info

Publication number
FR3110165B1
FR3110165B1 FR2004868A FR2004868A FR3110165B1 FR 3110165 B1 FR3110165 B1 FR 3110165B1 FR 2004868 A FR2004868 A FR 2004868A FR 2004868 A FR2004868 A FR 2004868A FR 3110165 B1 FR3110165 B1 FR 3110165B1
Authority
FR
France
Prior art keywords
tumor tissue
fluorescent compounds
new fluorescent
tissue labeling
labeling
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2004868A
Other languages
English (en)
French (fr)
Other versions
FR3110165A1 (fr
Inventor
Joanne Tran-Guyon
Vincent Guyon
François Scherninski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proimaging SARL
Original Assignee
Proimaging SARL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2004868A priority Critical patent/FR3110165B1/fr
Application filed by Proimaging SARL filed Critical Proimaging SARL
Priority to US17/925,434 priority patent/US20230203014A1/en
Priority to EP21732450.8A priority patent/EP4149925A1/fr
Priority to PCT/FR2021/050832 priority patent/WO2021229188A1/fr
Priority to CN202511568024.1A priority patent/CN121471129A/zh
Priority to CN202180035401.9A priority patent/CN115605459A/zh
Priority to KR1020227043701A priority patent/KR20230010713A/ko
Priority to JP2023514171A priority patent/JP2023525601A/ja
Priority to CA3178232A priority patent/CA3178232A1/fr
Priority to BR112022023154A priority patent/BR112022023154A2/pt
Publication of FR3110165A1 publication Critical patent/FR3110165A1/fr
Application granted granted Critical
Publication of FR3110165B1 publication Critical patent/FR3110165B1/fr
Priority to JP2025284837A priority patent/JP2026042845A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/006—Biological staining of tissues in vivo, e.g. methylene blue or toluidine blue O administered in the buccal area to detect epithelial cancer cells, dyes used for delineating tissues during surgery
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K11/00—Luminescent materials, e.g. electroluminescent or chemiluminescent
    • C09K11/06—Luminescent materials, e.g. electroluminescent or chemiluminescent containing organic luminescent materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
    • C09K2211/10—Non-macromolecular compounds
    • C09K2211/1018—Heterocyclic compounds
    • C09K2211/1025—Heterocyclic compounds characterised by ligands
    • C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Surgery (AREA)
  • Materials Engineering (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FR2004868A 2020-05-15 2020-05-15 Nouveaux composés fluorescents pour le marquage de tissu tumoral Active FR3110165B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR2004868A FR3110165B1 (fr) 2020-05-15 2020-05-15 Nouveaux composés fluorescents pour le marquage de tissu tumoral
CA3178232A CA3178232A1 (fr) 2020-05-15 2021-05-12 Nouveaux composes fluorescents pour le marquage de tissu tumoral
PCT/FR2021/050832 WO2021229188A1 (fr) 2020-05-15 2021-05-12 Nouveaux composés fluorescents pour le marquage de tissu tumoral
CN202511568024.1A CN121471129A (zh) 2020-05-15 2021-05-12 用于标记肿瘤组织的新型荧光化合物
CN202180035401.9A CN115605459A (zh) 2020-05-15 2021-05-12 用于标记肿瘤组织的新型荧光化合物
KR1020227043701A KR20230010713A (ko) 2020-05-15 2021-05-12 종양 조직 표지를 위한 새로운 형광 화합물
US17/925,434 US20230203014A1 (en) 2020-05-15 2021-05-12 Novel fluorescent compounds for labeling tumor tissue
EP21732450.8A EP4149925A1 (fr) 2020-05-15 2021-05-12 Nouveaux composés fluorescents pour le marquage de tissu tumoral
BR112022023154A BR112022023154A2 (pt) 2020-05-15 2021-05-12 Compostos, método para preparar os mesmos, uso dos referidos compostos, métodos para marcar e detectar tecido tumoral e composição
JP2023514171A JP2023525601A (ja) 2020-05-15 2021-05-12 腫瘍組織を標識するための新規蛍光化合物
JP2025284837A JP2026042845A (ja) 2020-05-15 2025-12-26 腫瘍組織を標識するための新規蛍光化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2004868 2020-05-15
FR2004868A FR3110165B1 (fr) 2020-05-15 2020-05-15 Nouveaux composés fluorescents pour le marquage de tissu tumoral

Publications (2)

Publication Number Publication Date
FR3110165A1 FR3110165A1 (fr) 2021-11-19
FR3110165B1 true FR3110165B1 (fr) 2022-10-28

Family

ID=72644317

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2004868A Active FR3110165B1 (fr) 2020-05-15 2020-05-15 Nouveaux composés fluorescents pour le marquage de tissu tumoral

Country Status (9)

Country Link
US (1) US20230203014A1 (https=)
EP (1) EP4149925A1 (https=)
JP (2) JP2023525601A (https=)
KR (1) KR20230010713A (https=)
CN (2) CN115605459A (https=)
BR (1) BR112022023154A2 (https=)
CA (1) CA3178232A1 (https=)
FR (1) FR3110165B1 (https=)
WO (1) WO2021229188A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023150222A1 (en) * 2022-02-02 2023-08-10 Vergent Bioscience, Inc. Methods for localization of cancerous tissue using fluorescent molecular imaging agent for diagnosis or treatment
CN114751907A (zh) * 2022-03-17 2022-07-15 南京诺源医疗器械有限公司 一种主动靶向叶酸受体近红外荧光分子及其制备方法和用途
CN116947829B (zh) * 2023-07-05 2025-09-23 上海内瑟汐医疗科技有限公司 一种基于新吲哚菁绿ir820的荧光化合物及其制备和应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06145539A (ja) * 1992-11-04 1994-05-24 Fuji Photo Film Co Ltd シアニン化合物
JPH07287346A (ja) * 1994-04-08 1995-10-31 E I Du Pont De Nemours & Co 近赤外ハレーション防止用の新規なエーテル色素を有する写真エレメント
GB2337523A (en) * 1998-04-29 1999-11-24 Nycomed Imaging As Light imaging contrast agents
JP2005220045A (ja) * 2004-02-04 2005-08-18 Konica Minolta Medical & Graphic Inc 蛍光造影剤
CN102268191B (zh) * 2010-06-06 2013-08-14 史春梦 七甲川吲哚花菁染料及其合成方法和应用
CN103911017B (zh) * 2012-12-28 2017-09-15 浙江海正药业股份有限公司 菁染料化合物及其制备方法、用于光动力学疗法的双重功能剂及其制备方法
CN105693590B (zh) * 2016-01-15 2019-01-15 复旦大学 一种pH控制识别肿瘤细胞的光热试剂及其制备方法和应用
KR101980292B1 (ko) * 2017-08-03 2019-05-20 (주)바이오액츠 형광 화합물 및 이의 제조방법
EP3517146A1 (en) * 2018-01-26 2019-07-31 Université de Strasbourg Fluorescent polymeric coating film for medical devices

Also Published As

Publication number Publication date
BR112022023154A2 (pt) 2023-02-07
FR3110165A1 (fr) 2021-11-19
US20230203014A1 (en) 2023-06-29
JP2023525601A (ja) 2023-06-16
JP2026042845A (ja) 2026-03-11
CA3178232A1 (fr) 2021-11-18
WO2021229188A1 (fr) 2021-11-18
EP4149925A1 (fr) 2023-03-22
CN115605459A (zh) 2023-01-13
KR20230010713A (ko) 2023-01-19
CN121471129A (zh) 2026-02-06

Similar Documents

Publication Publication Date Title
FR3110165B1 (fr) Nouveaux composés fluorescents pour le marquage de tissu tumoral
MA56508B1 (fr) Inhibiteur de l'egfr pour le traitement du cancer
BRPI0419234B8 (pt) pino intramedular
ATE518477T1 (de) Fluoreszenzvermittelte molekulartomographie
CA2589726C (en) Graphical user interface for tissue biopsy system
MX2021012221A (es) Inhibidor del cd73, metodo de preparacion y aplicacion del mismo.
BR112018008507A2 (pt) pneumático com camadas de trabalho que compreendem monofilamentos e com banda de rodagem ranhurada
FI20055417A0 (fi) Syöpäpesifiset glykaanit ja niiden käyttö
BRPI0418113A (pt) composto, composição farmacêutica, e, métodos para tratar um distúrbio prostático, para tratar um distúrbio angiogênico, para tratar um distúrbio patológico, para tratar uma doença ou distúrbio neurodegenerativos, para tratar mieloma múltiplo ou leucemia, para tratar cáncer de tumores sólidos e para tratar um tumor hematológico
ATE405533T1 (de) Verfahren zur ä11cü-radiomarkierung von phenthiazin und phenothiazinartige verbindungen
Siddachari et al. Laryngeal amyloidosis.
WO2024023262A3 (en) Nucleic acid compounds
WO2020251851A3 (en) Dna methylation biomarkers for cancer diagnosing and treatment
BRPI0412110A (pt) genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos
BR112023014247A2 (pt) Composições farmacêuticas para tratar cânceres de mama e métodos de usos destas
Moiyadi et al. Fluorescence-guided surgery of malignant gliomas based on 5-aminolevulinic acid: paradigm shifts but not a panacea
Bozdag et al. Synthesis of new 3-(2-mercapto-4-oxo-4H-quinazolin-3-yl)-benzenesulfonamides with strong inhibition properties against the tumor associated carbonic anhydrases IX and XII
Boormans et al. Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naive, node-positive prostate cancer
JP2004223261A (ja) 近位大腿骨用穿孔具
WO2024023267A3 (en) Nucleic acid compounds
BR0213486A (pt) Combinações que compreendem um inibidor seletivo de ciclooxigenase-2
MA37437B1 (fr) Kit de diagnostic du cancer de sein en réaction qpcr multiplex et son application dans l'évaluation du statut de la protéine her2 et le choix du traitement
Farrand et al. Epidermoid carcinoma of the breast
Malashetti An evaluation of preoperative high resolution computed tomography of temporal bone in cholesteatoma
Dellaretti et al. Fluorescein-guided surgery for malignant gliomas

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20211119

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7